Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2025
0mins
Source: PRnewswire
Transaction Overview: Labcorp has announced an agreement to acquire select assets of BioReference Health from OPKO Health, focusing on oncology-related clinical testing services in the U.S., which will enhance Labcorp's laboratory capabilities and solidify its leadership in cancer care.
Financial Details and Impact: The acquisition, valued at up to $225 million, is expected to generate annual revenues of approximately $85 million to $100 million for Labcorp and aims to provide greater access to high-quality laboratory services for patients and healthcare providers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 273.610
Low
270.00
Averages
304.45
High
325.00
Current: 273.610
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
LABCORP CEO ADAM SCHECHTER DISCLOSES SALE OF 8,705 COMMON SHARES ON MARCH 3 AT $279.9595 EACH, ACCORDING TO SEC FILING
Company Announcement: Labor Corp CEO Adam Schechter reports the open market sale of 8,705 common shares.
Sale Details: The shares were sold on March 3 at a price of $279.95 per share, as disclosed in a SEC filing.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Labcorp Expands Collaboration with PathAI for Digital Pathology
- Digital Pathology Expansion: Labcorp announced an expansion of its collaboration with PathAI to deploy the FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations, aiming to enhance the digitalization of pathology workflows.
- Cloud Workflow Support: The platform will support fully digital workflows for slide review, case management, and collaboration, integrating AI-powered image analysis technology to assist in diagnostics, thereby improving overall diagnostic accuracy.
- Precision Medicine Integration: Labcorp will also incorporate digital pathology workflows to support its precision medicine products, further advancing the company's strategic positioning in the personalized medicine sector.
- Continued Strategic Investment: This expansion builds on Labcorp's 2019 strategic investment in PathAI, indicating ongoing collaboration in AI-driven clinical trial support and validation of pathology solutions, which is expected to drive future growth for the company.
See More
Labcorp Expands Collaboration with PathAI for Digital Pathology
- Digital Pathology Deployment: Labcorp is expanding its collaboration with PathAI to deploy the FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital partnerships, aiming to enable pathologists to manage slides digitally through cloud technology.
- Workflow Digitization: The AISight Dx platform will facilitate fully digital workflows for case management, slide review, collaboration, and annotation, which not only enhances operational efficiency but also ensures more reliable quality and faster turnaround times.
- AI Image Analysis Integration: This platform integrates AI-powered image analysis and secure storage capabilities, allowing pathologists to perform key steps in the diagnostic process more efficiently, thereby improving overall diagnostic capabilities.
- Precision Medicine Support: Labcorp will incorporate digital pathology workflows into its precision medicine products, marking a continuation of its 2019 strategic investment in PathAI while further advancing AI-driven clinical trial support and validation of novel AI pathology solutions.
See More
Labcorp Expands Collaboration with PathAI for AISight® Dx Deployment
- Digital Pathology Deployment: Labcorp has announced an expanded collaboration with PathAI to deploy the AISight® Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations, aiming to enhance workflow efficiency and patient care quality.
- AI Integration: The platform enables pathologists to digitally view and manage slides via cloud technology and utilize AI to support key diagnostic steps, resulting in faster and more consistent outcomes that improve clinical service quality.
- Strategic Investment Continuation: This expansion builds on Labcorp's 2019 strategic investment in PathAI, further advancing AI-driven clinical trial support and validation of novel AI pathology solutions, demonstrating the company's ongoing commitment to the digital pathology field.
- Global Impact Enhancement: Labcorp's leadership position makes it an ideal partner for modernizing pathology, and the nationwide deployment of AISight Dx will extend high-quality, efficient digital pathology services to a broader market, strengthening the company's competitive edge in the healthcare industry.
See More
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
LABCORP CEO ADAM SCHECHTER DISCLOSES SALE OF 8,705 COMMON SHARES ON MARCH 3 AT $279.9595 EACH, ACCORDING TO SEC FILING
Company Announcement: Labor Corp CEO Adam Schechter reports the open market sale of 8,705 common shares.
Sale Details: The shares were sold on March 3 at a price of $279.95 per share, as disclosed in a SEC filing.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Labcorp Expands Collaboration with PathAI for Digital Pathology
- Digital Pathology Expansion: Labcorp announced an expansion of its collaboration with PathAI to deploy the FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations, aiming to enhance the digitalization of pathology workflows.
- Cloud Workflow Support: The platform will support fully digital workflows for slide review, case management, and collaboration, integrating AI-powered image analysis technology to assist in diagnostics, thereby improving overall diagnostic accuracy.
- Precision Medicine Integration: Labcorp will also incorporate digital pathology workflows to support its precision medicine products, further advancing the company's strategic positioning in the personalized medicine sector.
- Continued Strategic Investment: This expansion builds on Labcorp's 2019 strategic investment in PathAI, indicating ongoing collaboration in AI-driven clinical trial support and validation of pathology solutions, which is expected to drive future growth for the company.
See More
Labcorp Expands Collaboration with PathAI for Digital Pathology
- Digital Pathology Deployment: Labcorp is expanding its collaboration with PathAI to deploy the FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital partnerships, aiming to enable pathologists to manage slides digitally through cloud technology.
- Workflow Digitization: The AISight Dx platform will facilitate fully digital workflows for case management, slide review, collaboration, and annotation, which not only enhances operational efficiency but also ensures more reliable quality and faster turnaround times.
- AI Image Analysis Integration: This platform integrates AI-powered image analysis and secure storage capabilities, allowing pathologists to perform key steps in the diagnostic process more efficiently, thereby improving overall diagnostic capabilities.
- Precision Medicine Support: Labcorp will incorporate digital pathology workflows into its precision medicine products, marking a continuation of its 2019 strategic investment in PathAI while further advancing AI-driven clinical trial support and validation of novel AI pathology solutions.
See More
Labcorp Expands Collaboration with PathAI for AISight® Dx Deployment
- Digital Pathology Deployment: Labcorp has announced an expanded collaboration with PathAI to deploy the AISight® Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations, aiming to enhance workflow efficiency and patient care quality.
- AI Integration: The platform enables pathologists to digitally view and manage slides via cloud technology and utilize AI to support key diagnostic steps, resulting in faster and more consistent outcomes that improve clinical service quality.
- Strategic Investment Continuation: This expansion builds on Labcorp's 2019 strategic investment in PathAI, further advancing AI-driven clinical trial support and validation of novel AI pathology solutions, demonstrating the company's ongoing commitment to the digital pathology field.
- Global Impact Enhancement: Labcorp's leadership position makes it an ideal partner for modernizing pathology, and the nationwide deployment of AISight Dx will extend high-quality, efficient digital pathology services to a broader market, strengthening the company's competitive edge in the healthcare industry.
See More
